June 13, 2022
SomaLogic inks license deal with OncoHost to develop precision cancer diagnostics
Original source here.
- SomaLogic (NASDAQ:SLGC) on Monday said it had signed a licensing agreement with Israel-based OncoHost for the development of precision cancer diagnostics.
- As per the agreement, OncoHost will license SLGC’s SomaScan Platform to develop proteomics tests for its PROphet diagnostic system, which analyzes and monitors biological processes in a patient in response to a given cancer therapy.
- As part of the deal, OncoHost will establish a lab in North Carolina where it will use the SomaScan Assay kits to run protein measurements on patient samples.
January 26, 2024
OncoHost’s CEO Is PROphet-ic About His Diagnostic’s Potential To Transform Care
January 4, 2024
Predicting Immune-Related Adverse Events Through Machine Learning With OncoHost: Dr. Waqas Haque, Dr. Matthew Hadfield, and Dr. Ofer Sharon
Read all news